Biological Psychiatry Global Open Science
July 1, 2025
Yalin Sun, Meenalochani Sivasubramanian, Marija Milenkovic et al.
Adolescent-onset cannabis use confers higher risk for neuropsychiatric disorders, implicating amygdala dysfunction. However, the mechanisms that mediate Δ9-tetrahydrocannabinol (THC)-triggered neuroadaptive changes in the maturing amygdala remain unclear. Proteomic analysis of amygdala tissue from male adolescent Saimiri boliviensis nonhuman primates chronically treated with THC provided leads...
Biological Psychiatry Global Open Science
July 2023
Ahmed Hasbi, Bertha K. Madras, Susan R George
Frequent cannabis use is associated with a higher risk of developing cannabis use disorder and other adverse consequences. However, rodent models studying the underlying mechanisms of the reinforcing and withdrawal effects of the primary constituent of cannabis, Δ9-tetrahydrocannabinol (THC), have been limited. This study investigated the effects of daily THC (1 mg/kg, intraperitoneal, 9 days)...
Brain Science
February 1, 2023
Ahmed Hasbi, Bertha K. Madras, S. George
Background: There is a growing liberalization of cannabis-based preparations for medical and recreational use. In multiple instances, anxiety and depression are cited as either a primary or a secondary reason for the use of cannabinoids. Aim: The purpose of this review is to explore the association between depression or anxiety and the dysregulation of the endogenous endocannabinoid system...
Current Research in Neurobiology
2023
Marie-Eve Di Raddo, Marija Milenkovic, Meenalochani Sivasubramanian et al.
Earlier age of cannabis usage poses higher risk of Cannabis Use Disorder and adverse consequences, such as addiction, anxiety, dysphoria, psychosis, largely attributed to its principal psychoactive component, Δ9-tetrahydrocannabinol (THC) and altered dopaminergic function. As dopamine D1-D2 receptor heteromer activation causes anxiety and anhedonia, this signaling complex was postulated to...
New England Journal of Medicine
November 2, 2022
Bertha K. Madras
36 citations
Depression ranks first among psychiatric disorders that dominate the global burden of disease, posing a substantial personal strain and economic drain on nations.1 At least 30 drugs are Food and Drug Administration (FDA)–approved to treat depression,2 yet a systematic review and meta-analysis of 22 antidepressants concluded that although they were more effective than placebo in adults with...
Journal of Psychopharmacology
January 21, 2008
Christopher D. Verrico, Laurie J. Lynch, Michele A. Fahey et al.
31 citations
Human MDMA (R,S-3,4-methylenedioxymethamphetamine) users display selective cognitive deficits after acute MDMA exposure, frequently attributed to serotonin deficits. We postulated that MDMA will compromize executive function in primates and that an inhibitor of the serotonin transporter (SERT) and the norepinephrine transporter (NET) but not the dopamine (DAT) transporter, will prevent...